

***Plasmodium knowlesi* infection is associated with elevated circulating biomarkers of brain injury and endothelial activation**

1

2 **Cesc Bertran-Cobo^{1,2,3} □, Elin Dumont¹ □, Naqib Rafieqin Noordin⁴, Meng-Yee Lai⁴, William**
3 **Stone¹, Kevin KA Tetteh¹ Ψ, Chris Drakeley¹, Sanjeev Krishna^{4,5,6,7}, Yee-Ling Lau⁴ †*, Samuel C**
4 **Wassmer¹ †***

5

6 ¹Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK

7 ²Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa

8 ³Neuroscience Institute, University of Cape Town, Cape Town, South Africa

9 ⁴Department of Parasitology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia

10 ⁵Institut Für Tropenmedizin, Eberhard Karls Universität Tübingen, Tübingen, Germany

11 ⁶Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon

12 ⁷Clinical Academic Group in Institute for Infection & Immunity, St George's University of London,
13 London, UK

14 Ψ Current affiliation: FIND, Campus Biotech, Chemin des Mines 9, 1202, Geneva, Switzerland

15 □ These authors share first authorship.

16 † These authors share last authorship.

17

18 *** Correspondence:**

19 Prof Dr Yee-Ling Lau, Universiti Malaya, Kuala Lumpur, Malaysia

20 lauyeeling@um.edu.my

21 Dr Samuel C Wassmer, London School of Hygiene and Tropical Medicine, London, UK

22 Sam.Wassmer@lshtm.ac.uk

23

24 **Keywords:** *Plasmodium knowlesi*, malaria, brain, vascular dysfunction, Malaysia

25

26 **Abstract**

27 Introduction: Malaria remains a major public health concern with substantial morbidity and mortality
28 worldwide. In Malaysia, the emergence of *Plasmodium knowlesi* has led to a surge in zoonotic
29 malaria cases and deaths in recent years. Signs of cerebral involvement have been observed in a
30 non-comatose, fatal case of severe knowlesi infection, but the potential impact of this malaria
31 species on the brain remains underexplored. To address this gap, we investigated circulating levels
32 of brain injury, inflammation, and vascular biomarkers in a cohort of knowlesi-infected patients and
33 controls.

34 Methods: Archived plasma samples from 19 patients with confirmed symptomatic knowlesi infection
35 and 19 healthy, age-matched controls from Peninsular Malaysia were analysed. A total of 52 plasma
36 biomarkers of brain injury, inflammation, and vascular activation were measured using Luminex and
37 SIMOA assays. Wilcoxon tests were used to examine group differences, and biomarker profiles
38 were explored through hierarchical clustering heatmap analysis.

39 Results: Bonferroni-corrected analyses revealed significantly elevated brain injury biomarker levels
40 in knowlesi-infected patients, including S100B ($p < 0.0001$), Tau ($p = 0.0007$), UCH-L1 ($p < 0.0001$),
41 α Syn ($p < 0.0001$), Park7 ($p = 0.0006$), NRG1 ($p = 0.0022$), and TDP-43 ($p = 0.005$). Compared to
42 controls, levels were lower in the infected group for BDNF ($p < 0.0001$), CaBD ($p < 0.0001$), CNTN1
43 ($p < 0.0001$), NCAM-1 ($p < 0.0001$), GFAP ($p = 0.0013$), and KLK6 ($p = 0.0126$). Hierarchical clustering
44 revealed distinct group profiles for circulating levels of brain injury and vascular activation
45 biomarkers.

46 Conclusions: Our findings highlight for the first time the impact of *Plasmodium knowlesi* infection on
47 the brain, with distinct alterations in cerebral injury and endothelial activation biomarker profiles
48 compared to healthy controls. Further studies are warranted to investigate the pathophysiology and
49 clinical significance of these altered surrogate markers, through both neuroimaging and long-term
50 neurocognitive assessments.

51 **1 Introduction**

52 Malaria is a life-threatening, vector-borne infection caused by parasites of the genus *Plasmodium*
53 that led to an estimated 249 million cases worldwide and approximately 608,000 deaths in 2022 (1).
54 Malaria is endemic in Southeast Asia, where it poses a significant public health challenge. In
55 Malaysia, *P. falciparum* and *P. vivax* have historically been the species responsible for most malaria
56 infections and deaths, but thanks to national efforts in eradicating the disease, no indigenous cases
57 have been reported since 2018 (1). However, an emerging concern in the country is *P. knowlesi*
58 (*Pk*), a zoonotic species that has become a significant contributor to malaria infections in humans
59 locally (2,3), with a total of 19,625 *Pk* cases and 57 deaths reported in Malaysia since 2017,
60 including 2,500 cases and 9 deaths in 2022 alone (1). Malaysia accounts for most *Pk* infections
61 globally, and this species is currently the major cause of human malaria in the country (4–6).

62 One of the most severe manifestations of *Plasmodium falciparum* infection is cerebral malaria, a life-
63 threatening neurological complication characterized by coma (7) and pathological hallmarks such as
64 petechial hemorrhages and parasite sequestration in the brain vasculature (8,9). Neurocognitive
65 sequelae are frequent in survivors and can persist long after the infection has been treated (10,11).
66 While cerebral malaria is predominantly associated with *P. falciparum* (7), recent case reports have
67 highlighted instances of cerebral involvement and severe neurological complications in patients
68 infected with other *Plasmodium* species (12–18). A high proportion of severe *Pk* infections has been
69 reported in Southeast Asia (5,19), as well as fatal cases (18–20). A recent study also showed that,
70 similarly to *P. falciparum*, *Pk*-infected erythrocytes are able bind to endothelial cells (21). Post-
71 mortem findings in one fatal case of severe *Pk* malaria revealed brain pathology features similar to
72 those seen in fatal falciparum cerebral malaria, including *Pk*-infected erythrocytes sequestration in
73 the microvasculature (18), suggesting that *Pk* malaria may also affect the brain. Remarkably, coma
74 was not observed in this patient (18), which contrasts with the World Health Organization (WHO)
75 definition of cerebral malaria caused by *P. falciparum* (7).

76 We recently reported that patients with severe and uncomplicated *falciparum* malaria —and
77 therefore without coma— have a wide range of brain changes detected using magnetic resonance
78 imaging (MRI) (22,23). Severe malaria patients from our cohort had elevated plasma levels of the
79 neurotrophic factor S100 calcium-binding protein β (S100B), a biomarker associated with central
80 nervous system insults (24,25), which correlated with brain MRI features typically found in cerebral
81 malaria (22). Overall, our findings suggest that there is a frequent and unrecognized impact of
82 malaria infection on the brain in *falciparum* malaria, irrespective of coma. These effects are likely
83 aggravated by acute kidney injury (AKI), with potential long-lasting repercussions on quality of life
84 and productivity in survivors (26).

85 Despite the similar pathologies reported between cerebral malaria and fatal *Pk* infection (18) and the
86 high incidence of kidney dysfunction in severe *Pk* malaria (27), the potential impact of *Pk* infection
87 on the human brain remains largely unexplored. To bridge this important knowledge gap, we
88 quantified plasma biomarkers of brain injury, vascular activation, and inflammation in a cohort of
89 Malaysian *Pk*-infected patients and healthy controls.

90

91 **2 Methods**

92 **2.1 Participants and samples**

93 This study leveraged archived plasma samples from patients aged 18 years and above with malaria
94 symptoms attending either a government hospital or private clinic in Johor, Selangor, Pahang,
95 Perak, and Trengganu states between December 2019 and January 2023 (**Figure 1**). Recruitment
96 of community-matched, age-matched uninfected controls was conducted via active screening of
97 individuals from communities in Johor, Selangor, Negeri Sembilan, and Kedah. Subjects were
98 approached for participation if they had no fever, were aged 18 years and above, and were part of
99 any of the considered high-risk groups. A high-risk group is defined as individuals working in
100 proximity with forest and forest fringes, i.e., servicemen, farmers, hunters, and natural resource
101 collectors (2,28).

102 Data collection procedures are described elsewhere (29). Briefly, samples were acquired using
103 EDTA anti-coagulant tubes. Informed consent was obtained prior to sample collection. All
104 participants were allowed sufficient time to consider their participation in the project. Individual data
105 were collected and recorded anonymously. *Plasmodium* infection and speciation in each collected
106 sample were confirmed by microscopic examination of Giemsa-stained blood smears and nested
107 polymerase chain reaction (PCR) based on the 18S rRNA gene. Out of the 50 individuals sampled
108 as part of the parent project, 38 had associated clinical information needed for this study, including
109 parasitemia. The de-identified Malaysian samples, consisting of 19 infected patients and 19 healthy
110 controls, were analysed.

111 **2.2 Biomarker panel selection**

112 A total of 52 plasma biomarkers were selected, including 21 markers of brain alterations or cerebral
113 injury, 21 markers of infection and immune activation, and 10 vascular biomarkers. Our literature
114 review-based selection followed the assumption that any plasma biomarker ever reported to be

115 altered in any species of human malaria could potentially be altered in our cohort of *Pk* patients. For
116 brain injury biomarkers, a second premise applied: since cerebral malaria can cause long-lasting
117 cognitive disorders (10,11), any plasma marker reported to be increased or decreased in cognitively
118 impaired subjects (e.g., neurodegenerative diseases, traumatic brain injury, etc) could also be
119 altered in our patients.

120 To inform the biomarker panel selection, a systematic search of scientific literature on biomarker
121 plasma levels in human patients was conducted in PubMed database, including all relevant
122 publications from 2010 onwards. The results of this systematic search are comprehensively
123 summarized in **Table 1** (brain injury biomarkers), **Supplementary Table 1** (infection and immune
124 activation biomarkers) and **Supplementary Table 2** (vascular biomarkers).

125 **2.3 Measurement of plasma biomarker levels via Luminex and SIMOA assays**

126 Thirty-eight biomarkers were analysed using the customizable Human Luminex® Discovery Assay
127 provided by R&D Biotechne (catalogue ref.: LXSAHM): Alpha-Synuclein (α Syn), Amyloid-beta
128 precursor protein (APP), Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2), Bone Morphogenetic
129 Protein 9 (BMP-9), Calbindin D (CaBP), Chemokine Ligand 2 (CCL2), Chemokine Ligand 4 (CCL4),
130 Chemokine Ligand 5 (CCL5), Chemokine Ligand 18 (CCL18), Contactin-1 (CNTN1), C-Reactive
131 Protein (CRP), Enolase 2 / Neuron-specific Enolase (ENO2/NSE), Fetuin A, Granulocyte-
132 Macrophage Colony-Stimulating Factor (GM-CSF), Interferon Gamma (IFN- γ), Intercellular
133 Adhesion Molecule 1 (ICAM-1), Interleukin 1 alpha (IL-1 α), Interleukin 1 beta (IL-1 β), Interleukin
134 1RA (IL-1RA), Interleukin 2 (IL-2), Interleukin 4 (IL-4), Interleukin 6 (IL-6), Interleukin 8 (IL-8),
135 Interleukin 10 (IL-10), Interleukin 17 (IL-17A), Lipocalin-2 (NGAL), Myeloperoxidase (MPO),
136 Osteopontin (OPN), Parkinsonism associated deglycase (Park7), Platelet-Derived Growth Factor AA
137 (PDGF-AA) and BB (PDGF-BB), Receptor for Advanced Glycation Endproducts (RAGE), Serine
138 Proteinase Inhibitor clade E1 (Serpine E1), Tumour Necrosis Factor alpha (TNF- α), Vascular Cell

139 Adhesion Molecule (VCAM-1), Vascular Endothelial Growth Factor (VEGF), and von Willebrand
140 Factor A2 domain (vWF-A2).

141 Additionally, 10 biomarkers were analysed using the Neuroscience 18-plex Human ProcartaPlex™
142 Panel assay provided by ThermoFisher Scientific Invitrogen™ (catalogue ref.: EPX180-15837-901):
143 Amyloid beta (1-42) ($A\beta_{(1-42)}$), Brain-Derived Neurotrophic Factor (BDNF), Kallikrein 6 (KLK6),
144 Migration Inhibitory Factor (MIF), Nerve Growth Factor beta (NGF- β), Neural Cell Adhesion
145 Molecule (NCAM-1), Neurogranin (NRGN), S100 calcium-binding protein β (S100 β), TAR DNA-
146 binding protein 43 (TDP-43), and Chitinase-3-like protein 1 (YKL-40).

147 Serum levels of biomarkers screened via the Human Luminex® Discovery Assay (#LXSAHM) and
148 the Neuroscience 18-plex Human ProcartaPlex™ Panel (#EPX180-15837-901) were measured
149 using a MAGPIX® bioanalyzer, according to manufacturer's instructions. Singlicate measurements
150 were taken of each sample. Sample concentrations were extrapolated from a standard curve, fitted
151 using a 6-parameter logistic algorithm. Luminex technology is a multiplex assay platform that allows
152 for the simultaneous measurement of multiple biomarkers in a single plasma sample and can detect
153 molecule concentrations in the picogram range. The use of Luminex technology in the study of
154 biomarkers of brain injury is widely extended (30) due to its high sensitivity and reproducibility.

155 Lastly, 4 brain injury biomarkers were analysed using the highly sensitive single molecule
156 immunoassay (SIMOA), using the Human Neurology 4-Plex A assay provided by Quanterix
157 (catalogue ref.: 102153): Neurofilament light (NfL), total Tau protein (Tau), Glial Fibrillary Acidic
158 Protein (GFAP), and Ubiquitin Carboxyl-terminal Hydrolase L1 (UCH-L1). Levels of biomarkers
159 screened via the SIMOA Human Neurology 4-Plex A assay (#102153) were measured using a
160 SIMOA HD-X™ Analyzer (Quanterix), according to manufacturer's instructions. Briefly, samples
161 were thawed at 21°C, and centrifuged at 10,000 RCF for five minutes at the same temperature. On-
162 board the instrument, samples were diluted 1:4 with sample diluent and bound to paramagnetic
163 beads coated with a capture antibody specific for human GFAP, NfL, Tau, and UCH-L1. GFAP, NfL,

164 Tau, and UCH-L1 bound beads were then incubated with a biotinylated GFAP, NfL, Tau, and UCH-
165 L1 detection antibodies in turn conjugated to streptavidin- β -galactosidase complex that acts as a
166 fluorescent tag. Subsequent hydrolysis reaction with a resorufin β -D-galactopyranoside substrate
167 produces a fluorescent signal proportional to the concentration of GFAP, NfL, Tau, and UCH-L1
168 present. Singlicate measurements were taken of each sample. Sample concentrations were
169 extrapolated from a standard curve, fitted using a 4-parameter logistic algorithm. SIMOA is an
170 ultrasensitive digital immunoassay that allows for the detection and quantification of low-abundance
171 plasma biomarkers with sub-femtomolar sensitivity, high specificity, and high reproducibility (31).

172 **2.4 Serological assessment of malaria exposure via Luminex immunoassay**

173 As past infections with *Plasmodium* spp. could also influence observed biomarker levels across
174 participants, total IgG antibody responses of all *Pk*-infected patients and healthy controls were
175 measured using a multiplex bead-based immunoassay built on Luminex® xMAP® technology to
176 assess previous exposure to *P. knowlesi* as well as *P. falciparum*, *P. vivax*, *P. malariae*, and *P.*
177 *ovale*. Sera were screened against a previously optimised panel of 14 blood-stage antigens
178 representing varied markers of malaria exposure, listed in **Supplementary Table 3**. This
179 incorporated 6 *Pk* antigens: *PkAMA1* and *PkMSP1₁₉*, historical (long-term) exposure markers that
180 can persist in blood for several years with repeated infections, *PkSera3 Ag2* and *PkSSP2/TRAP*,
181 which have previously been utilised as markers in seroprevalence studies on Malaysian populations
182 (32–34), and *Pk1* and *Pk8*, exploratory antigens that demonstrated high immunogenicity in
183 preliminary data from assay screenings of pooled sera from *Pk*-infected Malaysian hyperimmune
184 individuals (**K. Tetteh, personal communication**). For *P. falciparum* and *P. vivax*, markers of
185 historical exposure, *Pf / PvMSP1₁₉* and *Pf / PvAMA1*, and markers of recent (short-term) exposure
186 known to persist in blood for up to 6-12 months following infection, *PfEtramp5 Ag1* and *PvRBP 2b*,
187 were included (35,36). *PmMSP1₁₉* and *PoMSP1₁₉* were used to assess historical exposure to *P.*
188 *malariae* and *P. ovale*, respectively. Additionally, tetanus toxoid vaccine protein from *Clostridium*

189 *tetani* and glutathione-S-transferase (GST) from *Schistosoma japonicum* were included as non-
190 malaria internal assay controls (37).

191 The Luminex assay was performed as previously described (38). Briefly, based on previously
192 identified antigen-specific optimal EC₅₀ concentrations, each antigen was covalently coupled to a
193 colour-coded MagPlex® bead region (MagPlex, Luminex Corp., Austin, TX) via N-
194 Hydroxysuccinimide/1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (NHS/EDC) chemistry. Test
195 sera were prepared at 1/400 in diluent buffer (1x Phosphate Buffer Saline (PBS); 0.05% Tween® 20;
196 0.5% bovine serum albumin; 0.02% sodium azide; 0.1% casein; 0.5% polyvinyl alcohol; 0.5%
197 polyvinylpyrrolidone; 15.25ug/mL *E. coli* lysate) and incubated at 4°C overnight. Antigen-coupled
198 beads were incubated with 50µL of diluted samples and incubated for 90 minutes at room
199 temperature with shaking at 600 RPM before incubation with 50µL of 1/200 R-Phycoerythrin-
200 conjugated AffiniPure F(ab')₂ Fragment Goat Anti-Human IgG secondary antibody
201 (JacksonImmunoResearch; 109-116-098) for 90 minutes under the same conditions (38).

202 Pooled sera from hyperimmune individuals in Malaysia (*Pk+*), Tanzania (CP3), and Peru (S1) were
203 included as *Pk*, *P. falciparum*, and *P. vivax* positive controls, respectively, in 6-point 5-fold serial
204 dilution curves (1/10 - 1/31250). Commercial WHO reference reagents for anti-*P. falciparum*
205 (10/198) human serum and anti-*P. vivax* (19/198) human plasma were also added as positive
206 controls at 1/400 and 1/4000. Public Health England (PHE) malaria naïve human sera (n=30) were
207 included as negative controls at 1/400. Two wells of diluent buffer served as blank controls to allow
208 subtraction of background signal. The plates were read using the MAGPIX® instrument (Luminex
209 Corp., Austin, TX) with the raw data recorded as Median Fluorescent Intensity (MFI) values using an
210 acquisition target of ≥30 beads per region per well. The data were background-adjusted and
211 normalised as described by Wu *et al* (38).

212 **2.5 Statistical analysis**

213 Sociodemographic characteristics of the participants were reported as mean (\pm SD) for continuous
214 data, or absolute frequencies (%) for categorical data. Continuous data was assessed for normality
215 using Shapiro-Wilk tests. Comparisons between *Pk*-infected cases and healthy controls were made
216 using *t*-tests or Wilcoxon tests for normally and non-normally distributed continuous data,
217 respectively, and χ^2 tests for categorical data.

218 Differences in levels of individual biomarkers between *Pk*-infected patients and controls were
219 examined using two-tailed *t*-tests and Wilcoxon tests for normally and non-normally distributed data,
220 respectively. Bonferroni correction for multiple comparisons was applied. Correlation matrixes were
221 used to visualize the relationships between biomarker levels in both groups, with previous data
222 scaling. Any potential correlations between biomarker levels and demographic and clinical
223 parameters such as age and parasitemia were evaluated using Spearman's rank correlation
224 coefficient.

225 To elucidate potential profiles of biomarker levels that could distinguish between infected patients
226 and controls, a hierarchical clustering heatmap analysis was performed, prior scaling of biomarker
227 data. This provided a visual representation of the relationships between individuals based on the
228 similarity of their biomarker profiles. Initially, the analysis was conducted on the entire set of
229 biomarkers to comprehensively explore the clustering patterns within the dataset. Subsequently, the
230 clustering analysis was applied separately to subsets of biomarkers representing brain injury,
231 infection and immunity, and vascular biomarkers.

232 To assess malaria exposure, a hierarchical clustering heatmap was similarly performed to allow
233 visual comparison of individual antibody responses to *Pk*-specific antigen profiles across study
234 participants. Comparisons of group means of MFI responses between *Pk*-infected cases and
235 healthy controls were conducted using the non-parametric Kruskal-Wallis test with Dunn's correction
236 for multiple comparisons applied.

237 Statistical analyses were performed in R (version 4.3.1) with RStudio software (version 2023.09.1-
238 494). Data was visualized in R (version 4.3.1) with RStudio software (version 2023.09.1-494) and
239 GraphPad Prism 10. P values of less than 0.05 (two-tailed) were considered statistically significant.

240 3 Results

241 3.1 Cohort characteristics

242 All participants in our sub-study were male (N=38, 100%). Both *Pk*-infected patients and community-
243 matched, age-matched uninfected controls had an average age of 39 (\pm 15) years. In the *Pk*-infected
244 group, patients presented with median parasitemia 15,200.00 parasites/ μ L and 26,746.00
245 interquartile range.

246 3.2 Concentrations of individual markers between *Pk*-infected patients and controls

247 Biomarkers of brain injury: Bonferroni-corrected analyses revealed significantly higher plasma levels
248 of the following brain injury biomarkers in the *Pk*-infected group, compared with uninfected controls:
249 Tau ($p=0.0007$), UCH-L1 ($p<0.0001$), α Syn ($p<0.0001$), Park7 ($p=0.0006$), NRG1 ($p=0.0022$), and
250 TDP-43 ($p=0.005$). In contrast, levels of the following biomarkers were found to be significantly lower
251 in the *Pk*-infected group when compared with uninfected controls: CaBD ($p<0.0001$), CNTN1
252 ($p<0.0001$), NCAM-1 ($p<0.0001$), BDNF ($p<0.0001$), GFAP ($p=0.0013$), and KLK6 ($p=0.0126$).
253 Results obtained on CaBD and CNTN1 levels revealed clear cutoff values that allowed for subject
254 classification based on infection status: All *Pk*-infected patients (19/19, 100%) presented with
255 plasma CaBD levels below 1,400pg/mL or CNTN1 levels below 12,500pg/mL, whereas
256 concentrations in all uninfected controls (19/19, 100%) were above 1,400pg/mL for CNTN1 and
257 above 15,000pg/mL for CNTN1, respectively (**Figure 2, Supplementary Table 4**).

258 Since S100B and $A\beta_{(1-42)}$ plasma levels were below the range of detection in most uninfected
259 subjects, we first compared the proportion of individuals with detectable levels of these biomarkers
260 in each group using a Chi-square test with Yates' correction. The percentage of participants with
261 plasma levels within the range of detection was significantly higher in the *Pk*-infected group (19/19,
262 100%) than in the uninfected control group (4/19, 21.05%) ($p<0.0001$). Similarly for $A\beta_{(1-42)}$, the

263 proportion of individuals with detectable plasma levels in the *Pk*-infected group (17/19, 89.47%) was
264 significantly higher compared with their uninfected peers (7/19, 36.84%) ($p= 0.0025$).

265 To enable group comparisons for these two biomarkers, participants with values below the range of
266 detection were assigned a numerical value corresponding to half the value of the lower threshold of
267 detection. According to the manufacturer's information, these values were 27.31 pg/mL for S100B
268 and 0.22 pg/mL for $A\beta_{(1-42)}$. Achieved this, Wilcoxon tests revealed significantly higher plasma
269 S100B levels in the *Pk*-infected group, which survived Bonferroni correction for multiple
270 comparisons ($p<0.0001$), whereas no significant group differences were found for $A\beta_{(1-42)}$ plasma
271 levels.

272 Biomarkers of infection and immune activation: Group differences in plasma levels were found after
273 correction for multiple comparisons. IL-1RA ($p<0.0001$), IL-10 ($p<0.0001$), and MPO levels
274 ($p=0.0314$) were significantly higher in the *Pk*-infected group when compared with their uninfected
275 peers, whereas CCL4 ($p<0.0001$), CCL5 ($p<0.0001$), CRP ($p=0.0280$), and RAGE levels ($p=0.0025$)
276 were significantly lower (**Supplementary Figure 1, Supplementary Table 4**).

277 Biomarkers of vascular activation and injury: Ang-2/Ang-1 ratios ($p<0.0001$) and VCAM-1 levels
278 ($p=0.0001$) were significantly higher in *Pk*-infected patients compared with uninfected controls, while
279 Ang-1 ($p<0.0001$), BMP-9 ($p<0.0001$), PDGF-AA and -BB ($p<0.0001$), and Serpin E1 levels
280 ($p<0.0001$) were significantly lower (**Supplementary Figure 2, Supplementary Table 4**).

281 **3.3 Hierarchical clustering of samples based on biomarker blood levels**

282 Hierarchical clustering heatmap analyses revealed distinct group profiles for brain injury biomarkers
283 (**Figure 3A**). Most infected individuals clustered together (17/19, 89.47%), indicating a cohesive
284 pattern of elevated levels of Park7, S100B, α Syn, and TDP-43. Two infected individuals exhibited
285 atypical clustering with the healthy controls, suggesting a subgroup with a distinct biomarker profile.
286 In the control group (19/19, 100%), certain biomarkers, including BDNF, CaBD, CNTN1, and GFAP,

287 displayed higher levels and clustered together, representing a baseline biomarker profile in healthy
288 individuals. As mentioned, two infected individuals (2/19, 10.53%) clustered with the control group in
289 this category, indicating potential overlap or similarity in the levels of these specific biomarkers
290 between infected and control individuals.

291 Clustering of biomarkers associated with infection and immune activation did not reveal distinct
292 separation between the two groups (**Figure 3B**). Higher levels of IL-1RA and MPO predominantly
293 clustered in the infected group (17/19, 89.47%), and two control individuals also exhibited this
294 pattern (2/19, 10.53%). One infected individual (1/19, 5.26%) displayed very high levels of IL-1 β ,
295 GM-CSF, TNF- α , CCL4, and CCL2. Another infected individual (1/19, 5.26%) exhibited very high
296 levels of OPN and IL-10. Additionally, one control individual showed high levels of IL-6 (1/19,
297 5.26%).

298 Lastly, clustering of vascular biomarkers revealed clear and distinctive group profiles (**Figure 3C**). In
299 the control group (19/19, 100%), a cohesive cluster formed by high levels of PDGF AA, Ang-1,
300 PDGF BB, Serpin E1, and BMP-9 was observed. Conversely, in the infected group (19/19, 100%), a
301 distinct cluster of higher levels of VCAM-1 and the Ang-2/Ang-1 ratio was identified.

302 Correlations between biomarkers in each group can be observed in **Supplementary Figure 3**.

303 **3.4 Correlation of biomarker levels with age and parasitemia**

304 No significant correlations were identified between the levels of any of the examined biomarkers and
305 the age of participants within each respective group, as illustrated in **Supplementary Figure 4**.
306 Furthermore, within the *Pk*-infected group, no significant correlations were observed between
307 biomarker levels and the percentage of parasitemia (**Supplementary Figure 5**).

308 **3.5 Serological markers of previous malaria exposure**

309 Overall, the majority of participants generated low antibody responses across *Pk*, *P. vivax*, *P.*
310 *falciparum*, *P. ovale*, and *P. malariae* antigens with the exception of a few high responders
311 **(Supplementary Figure 6)**. Clustering of exposure markers in the hierarchical heatmap analysis did
312 not reveal distinct separation between responses of *Pk*-infected patients and uninfected controls
313 **(Supplementary Figure 7)**. Among *Pk* antigens, uninfected controls exhibited higher responses
314 against *Pk8* ($p < 0.0001$), *PkSERA3 Ag2* ($p = 0.0406$), and *Pk1* ($p = 0.0250$) than *Pk*-infected patients,
315 but no differences were observed for *PkAMA1* ($p > 0.9999$), *PkMSP1₁₉* ($p = 0.7778$), or *PkSSP2*
316 ($p = 0.2592$).

317 **4 Discussion**

318 Our study sheds light on the potential neurological implications of *Pk* infection in Malaysia. Through
319 the investigation of circulating levels of brain injury, inflammation, and vascular biomarkers in *Pk*-
320 infected patients compared to healthy controls, we uncovered compelling evidence suggesting a
321 significant impact of *Pk* infection on brain health. In line with previous reports suggesting
322 neurological involvement in severe malaria, our findings demonstrate increased levels of several
323 biomarkers associated with cerebral injury in *Pk*-infected patients. Notably, elevated levels of
324 S100B, Tau, UCH-L1, α Syn, Park7, NRG1, and TDP-43 signify potential brain damage in response
325 to *Pk* infection in our cohort.

326 Alterations in circulating levels of S100B, Tau, and UCH-L1 have been documented in previous
327 investigations of severe malaria. S100B, an abundant neurotrophic factor predominantly expressed
328 in astrocytes, serves as a biomarker of blood-brain barrier permeability and central nervous system
329 injury (39). Our group reported increased plasma levels of S100B in Indian patients with falciparum
330 severe malaria compared to uncomplicated cases (40). Similarly, levels of microtubule-associated
331 protein Tau, a neuropathological hallmark of Alzheimer's Disease and a biomarker for brain injury
332 (41), were found increased in the plasma of Ugandan children with severe falciparum malarial
333 anemia or cerebral malaria compared to uninfected controls. In cerebral malaria cases, Tau levels
334 correlated with mortality and persistent neurocognitive impairment in survivors (42). Lastly, plasma
335 levels of the ubiquitin-protein hydrolase UCH-L1, a marker of neuronal damage (43) were
336 significantly higher in Ugandan children with falciparum cerebral malaria and severe malarial anemia
337 compared with asymptomatic community children. The elevated plasma levels were associated with
338 surrogate markers of blood-brain barrier dysfunction and cognitive deficits over follow-up (44). Our
339 findings of increased S100B, Tau, and UCH-L1 plasma levels during *Pk* infection align with these
340 observations, suggesting potential cerebral involvement, neuronal injury, and blood-brain barrier
341 disruption in *knowlesi* malaria pathogenesis.

342 In broader clinical contexts, elevated circulating biomarkers in our *Pk*-infected cohort have been
343 associated with diverse conditions and are used as indicators of brain injury or dysfunction. For
344 instance, patients with Parkinson's Disease had significantly higher plasma levels of synaptic vesicle
345 trafficking regulator α Syn compared to healthy controls (45), and elevated levels of post-synaptic
346 protein NRG1 were associated with mild to acute traumatic brain injury (46,47), as well as neonatal
347 encephalopathy (48). The increased levels of α Syn and NRG1 in our *Pk*-infected patients suggest
348 potential neurological implications, prompting further investigation into the underlying mechanisms of
349 *knowlesi* malaria pathogenesis and their clinical significance over time.

350 In our study, several biomarkers were significantly decreased in *Pk*-infected individuals compared to
351 healthy controls, including GFAP, BDNF, CaBD, CNTN1, NCAM-1, and KLK6. The astrocytic
352 intermediate filament protein GFAP, used in clinical settings to assess severity of traumatic brain
353 injury (49), glymphatic function (50), and neurodegeneration (51,52), was not found to be elevated in
354 Ugandan children with falciparum cerebral malaria and severe malarial anemia (44). In contrast, the
355 observed differences in GFAP levels in our groups may suggest altered astroglial and/or glymphatic
356 functions in infected participants, supporting our hypothesis of cerebral involvement in *Pk* malaria.
357 Conversely, plasma levels of the neurotrophic factor BDNF, reported to be increased in early
358 Alzheimer's disease (53) and decreased in multiple sclerosis (54), were also lower in our study
359 participants, potentially indicating dysregulated neuroprotective mechanisms during *Pk* infection.
360 Furthermore, increased cerebrospinal fluid levels of CaBD, a protein involved in calcium
361 homeostasis and neuronal signalling, were associated with risk of dementia in cognitively normal
362 patients (55). CNTN1 and NCAM-1, two crucial factors for neural development and synaptic
363 formation, were decreased in our *Pk*-infected patients. Downregulated CNTN1 serum levels
364 predicted cognitive and motor declines in patients with Parkinson's Disease (56), while lower plasma
365 NCAM-1 levels correlated with cognitive impairment (57,58). Lastly, plasma levels of the
366 neuroinflammation modulator KLK6 were significantly increased in patients with advanced
367 Alzheimer's Disease compared with healthy controls (59). Although challenging to interpret, these

368 results suggest cerebral involvement during *Pk* infection and a potential risk of cognitive decline,
369 indicating a complex interplay between neuroinflammatory and neuroprotective mechanisms that
370 warrant further investigation.

371 Despite our expectations based on existing malaria literature (**Table 1**), we did not observe
372 significant group differences in levels of some biomarkers, such as the iron-trafficking protein
373 Lipocalin-2 (NGAL), a recognized biomarker of neuroinflammation (60). Elevated plasma NGAL
374 levels were associated with cerebral malaria in adult patients from India and distinguished between
375 fatal and nonfatal outcomes (61). Similarly, plasma NfL levels in Mozambican children with
376 uncomplicated and severe falciparum malaria showed no baseline group differences, but a
377 significant increase over time, particularly in severe malaria cases with neurological symptoms,
378 suggesting NfL as a potential follow-up biomarker of brain injury in malaria (62). Additionally, the
379 glycoprotein Fetuin A was previously reported as elevated in serum from Malaysian patients with *Pk*
380 malaria compared to uninfected controls (63). Lastly, plasma levels of the neurotrophic factor CNTF
381 were significantly reduced in Thai patients with cerebral malaria or severe malaria with renal failure,
382 compared to severe malaria cases without cerebral or renal involvement (64). Our findings,
383 diverging from anticipated outcomes, underscore the complexity of biomarker dynamics in infections
384 with different *Plasmodium* species and emphasize the need for further exploration in the context of
385 *Pk* malaria.

386 In our hierarchical clustering analysis, we observed distinct group profiles for brain injury biomarker
387 levels, indicating differences between *Pk*-infected patients and healthy controls. Most infected
388 individuals clustered together with elevated levels of specific biomarkers such as S100B, α Syn,
389 Park7, and TDP-43, suggesting a cohesive pattern of cerebral injury. However, two infected
390 individuals exhibited an atypical clustering with the healthy controls, hinting at potential subgroup
391 variability within the infected cohort, or different stages of disease progression. Conversely, in the
392 control group, several biomarkers including BDNF, GFAP, CaBD, and CNTN1 displayed higher
393 levels and clustered together, representing a baseline biomarker profile in healthy individuals. As

394 mentioned, two infected individuals clustered with the control group in this category, indicating
395 potential overlap or milder infection.

396 Clustering of vascular biomarkers revealed clear and distinctive group profiles. Uninfected
397 individuals formed a cohesive cluster with high levels of PDGF AA, Ang-1, PDGF BB, Serpin E1,
398 and BMP-9, revealing a healthy, baseline vascular profile. Conversely, the infected group cluster
399 had high levels of VCAM-1 and Ang-2/Ang-1 ratio, indicative of vascular involvement and endothelial
400 activation during *Pk* infection. The elevated Ang-2/Ang-1 ratio observed in our infected group aligns
401 with findings from previous studies on severe malaria caused by other *Plasmodium* species (65–70).
402 Similarly, increased levels of VCAM-1 have been reported in both falciparum and vivax malaria
403 infections (71,72). In contrast to brain injury and vascular biomarker profiles, hierarchical clustering
404 of biomarkers associated with infection and immune activation did not reveal distinct separation
405 between the two groups.

406 Lastly, total IgG antibody responses observed against *Plasmodium* spp. antigens, including *Pk*,
407 were low not only among most uninfected controls but also *Pk*-infected patients, and did not form
408 distinct clusters between the two groups. This suggests the cohort was largely malaria naïve, with
409 low reactivity to long-term infection markers *Pk/Pv/Pf/Pm/PoMSP1₁₉* and *Pk/Pv/PfAMA1* observed at
410 levels comparable to the PHE malaria naïve controls in all but two *Pk*-infected patients (73). As
411 naturally acquired responses against these antigens develop cumulatively with repeated exposure,
412 this indicates the occurrence of very few historical *Plasmodium* infections across participants (74).
413 This could highlight a lack of clinical immunity, rendering *Pk*-infected patients more susceptible to
414 potential malaria complications reflected in the brain and vascular biomarker profiles in this study,
415 though this was not possible to investigate due to insufficient clinical information. The lack of
416 elevated responses to *Pk* antigens SSP2, SERA3 Ag2, *Pk1* and *Pk8* may indicate there was
417 inadequate time for *Pk*-infected patients to mount a response prior to the sampling period (32).

418 Among uninfected controls, serological analyses identified two individuals exhibiting notably higher
419 responses: one control to *Pk* exploratory marker *Pk8* and *P. vivax* short-term exposure marker
420 *PvRBP2b*, and another also to *PvRBP2b*. Although this suggests previous exposures to *Pk* and *P.*
421 *vivax*, this did not appear to explain any atypical deviations in plasma biomarker levels observed in a
422 minority of individuals in this group.

423 Our study had several limitations. Firstly, the lack of detailed clinical information regarding malaria
424 severity and the presence or absence of renal failure among the *Pk*-infected group restricts our
425 ability to fully contextualize the observed alterations in brain injury biomarkers. While recent studies
426 have implicated AKI in the pathogenesis of brain injury (40) and long-term neurocognitive sequelae
427 (10,11), we were unable to directly investigate this relationship. Since AKI is a common complication
428 of knowlesi malaria (27), it is likely that similar distant organ pathways are involved, resulting in an
429 exacerbation of the brain changes (26). Secondly, our study did not include long-term follow-up
430 assessments to determine whether the elevated biomarker levels observed in *Pk*-infected patients
431 return to baseline or exhibit a steady increase over time. This would have been particularly relevant
432 for NfL, which increases in the weeks following cerebral insult and could provide valuable insights
433 into the persistence or resolution of brain injury following *Pk* infection (43,62). Lastly, a symptomatic,
434 non-malaria control group would allow stronger ascertainment of associations between biomarkers
435 and *Pk* infection.

436 In conclusion, our study represents the first comprehensive exploration of surrogate markers of
437 cerebral involvement in *Pk*-infected patients from Malaysia. Through the investigation of circulating
438 levels of brain injury, inflammation, and vascular biomarkers in *Pk*-infected patients compared to
439 healthy controls, we uncovered compelling evidence suggesting a significant impact of *Pk* infection
440 on brain and vascular health. The identification of distinct patterns in the clustering of biomarkers
441 associated with cerebral injury and endothelial dysfunction highlights the complex interplay between
442 these pathways during *Pk* infection. Our study lays the groundwork for further research to elucidate
443 the pathophysiology of this disease, and its potential long-term effects on the brain. Additional

444 investigations are urgently needed to assess structural and functional changes in the brain during
445 knowlesi malaria, through both neuroimaging and longitudinal neurocognitive evaluations. Our
446 findings not only contribute to our understanding of *Pk* malaria but may also have future implications
447 for the diagnosis, management, and therapeutic targeting of neurological complications associated
448 with this emerging infectious disease.

449

450 **5 Ethics approval and consent**

451 This study has been reviewed and approved by the Medical Research and Ethics Committee of the
452 Ministry of Health in Malaysia (reference NMRR ID 22-02557-1KV) and by the
453 Observational/Interventions Research Ethics Committee at the London School of Hygiene and
454 Tropical Medicine, UK (reference 27902). The shipment of samples from Malaysia to the UK was
455 performed in compliance with national and international regulations in both sites. The samples are
456 registered with the Human Tissue Authority, in accordance with UK national guidelines.

457

458 **6 Conflict of Interest**

459 The authors declare that the research was conducted in the absence of any commercial or financial
460 relationships that could be construed as a potential conflict of interest.

461

462 **7 Author Contributions**

463 **CBC:** conceptualization, methodology, investigation, formal analysis and interpretation, visualization,
464 writing – original draft, review & editing. **ED:** methodology, formal analysis and interpretation,
465 visualization, writing – review & editing. **NRN:** conceptualization, methodology, investigation, writing
466 – review & editing. **MYL:** conceptualization, methodology, investigation, writing – review & editing.
467 **KT:** methodology, investigation, resources, and writing – review & editing. **CD:** methodology,
468 investigation, resources, and writing – review & editing. **SK:** conceptualization, investigation, and
469 writing – review & editing. **YLL:** conceptualization, methodology, investigation, resources,
470 supervision, and writing – review & editing. **SCW:** conceptualization, methodology, investigation,
471 resources, supervision, and writing – review & editing. All authors approved the final version.

472

473 **8 Funding**

474 SCW is supported by the Medical Research Council UK under award number MR/S009450/1, and
475 the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH)
476 under award number U19AI089676. The content is solely the responsibility of the authors and does
477 not necessarily represent the official views of the NIH.

478

479 **9 Acknowledgments**

480 We extend our gratitude to the local health officers and personnel from Mersing, Kota Tinggi, and
481 Pejabat Kesihatan Daerah Kota Tinggi (Johor), Kuala Lipis and Kesihatan Betau (Pahang), Sungai
482 Siput (Perak), Kuala Kubu Bharu (Selangor), and Setiu (Trengganu) for their invaluable assistance
483 with sampling. We express our sincere appreciation to Dr Christian Bottomley, Ana Chopo-Pizarro,
484 and Helena Brazal Monzó at LSHTM for their invaluable insights, which greatly enhanced the quality
485 of this research.

486

487 **10 References**

- 488 1. WHO (2023). World Health Organization: World Malaria Report 2023.
- 489 2. Singh B, Sung LK, Matusop A, Radhakrishnan A, Shamsul SSG, Cox-Singh J, *et al.* A large focus of
490 naturally acquired *Plasmodium knowlesi* infections in human beings. *The Lancet* (2004)
491 363(9414):1017–24.
- 492 3. Barber BE, Grigg MJ, Cooper DJ, van Schalkwyk DA, William T, Rajahram GS, *et al.* Clinical
493 management of *Plasmodium knowlesi* malaria. *Adv Parasitol* (2021) 113:45–76.
- 494 4. Lai MY, Rafieqin N, Lee PY, Lee Z, Amir Rawa MS, Dzul S, *et al.* High incidence of *Plasmodium*
495 *knowlesi* malaria compared to other human malaria species in several hospitals in Malaysia. *Trop*
496 *Biomed* (2021) 38(3):248–53.
- 497 5. Kotepui M, Kotepui KU, Milanez GD, Masangkay FR. Prevalence of severe *Plasmodium knowlesi*
498 infection and risk factors related to severe complications compared with non-severe *P. knowlesi* and
499 severe *P. falciparum* malaria: a systematic review and meta-analysis. *Infect Dis Poverty* (2020) 9(1):1–
500 14.

- 501 6. Phang WK, Hamid MHA, Jelip J, Mudin RN, Chuang TW, Lau YL, *et al.* Spatial and Temporal Analysis
502 of *Plasmodium knowlesi* Infection in Peninsular Malaysia, 2011 to 2018. *International Journal of*
503 *Environmental Research and Public Health* (2020) 17(24):9271.
- 504 7. Severe malaria. *Trop Med Int Health* (2014) 19 Suppl 1:7–131.
- 505 8. Muppidi P, Wright E, Wassmer SC, Gupta H. Diagnosis of cerebral malaria: Tools to reduce
506 *Plasmodium falciparum* associated mortality. *Front Cell Infect Microbiol* (2023) 13:95.
- 507 9. Hadjilaou A, Brandi J, Riehn M, Friese MA, Jacobs T. Pathogenetic mechanisms and treatment targets
508 in cerebral malaria. *Nat Rev Neurol* (2023) 19(11):688–709.
- 509 10. Coughlan C, Jäger HR, Brealey D, Carletti F, Hyare H, Pattnaik R, *et al.* Adult Cerebral Malaria: Acute
510 and Subacute Imaging Findings, Long-term Clinical Consequences. *Clin Infect Dis* (2024) 78(2):457–
511 60.
- 512 11. Ssemata AS, Nakitende AJ, Kizito S, Thomas MR, Islam S, Bangirana P, *et al.* Association of severe
513 malaria with cognitive and behavioural outcomes in low- and middle-income countries: a meta-analysis
514 and systematic review. *Malar J* (2023) 22(1):1–12.
- 515 12. Mukhtar MM, Eisawi OA, Amanfo SA, Elamin EM, Imam ZS, Osman FM, *et al.* *Plasmodium vivax*
516 cerebral malaria in an adult patient in Sudan. *Malar J* (2019) 18(1):316–316.
- 517 13. Paredes-Obando M, Moreno A, Panduro-García E, Ferreyra A, Chuquipiondo-Galdos D, Ascate JJV,
518 *et al.* Malaria cerebral con pancitopenia por *Plasmodium vivax* en la Amazonía peruana: reporte de
519 caso. *Rev Peru Med Exp Salud Pública* (2022) 39(2):241–4.
- 520 14. Akhlaq A, Ghanchi NK, Usmani B, Shahzad R, Rahim A, Wasay M, *et al.* Neurological Complications in
521 Patients with *Plasmodium Vivax* Malaria from Karachi, Pakistan. *Journal of the Royal College of*
522 *Physicians of Edinburgh* (2018) 48(3):198–201.
- 523 15. Naing C, Whittaker MA, Nyunt Wai V, Mak JW. Is *Plasmodium vivax* Malaria a Severe Malaria?: A
524 Systematic Review and Meta-Analysis. *PLoS Negl Trop Dis* (2014) 8(8):e3071.
- 525 16. Rathia SK, Sankar J, Kandasamy D, Lodha R. *Plasmodium vivax* Malaria Presenting with Multifocal
526 Hemorrhagic Brain Infarcts in a School-going Child. *J Trop Pediatr* (2016) 62(4):341–4.
- 527 17. Tanwar GS, Khatri PC, Sengar GS, Kochar A, Kochar SK, Middha S, *et al.* Clinical profiles of 13
528 children with *Plasmodium vivax* cerebral malaria. *Ann Trop Paediatr* (2011) 31(4):351–6.
- 529 18. Cox-Singh J, Hiu J, Lucas SB, Divis PC, Zulkarnaen M, Chandran P, *et al.* Severe malaria - A case of
530 fatal *Plasmodium knowlesi* infection with post-mortem findings: A case report. *Malar J* (2010) 9(1):1–7.
- 531 19. Anstey NM, Grigg MJ, Rajahram GS, Cooper DJ, William T, Kho S, *et al.* Knowlesi malaria: Human risk
532 factors, clinical spectrum, and pathophysiology. *Adv Parasitol* (2021) 113:1–43.
- 533 20. Rajahram GS, Cooper DJ, William T, Grigg MJ, Anstey NM, Barber BE. Deaths From *Plasmodium*
534 *knowlesi* Malaria: Case Series and Systematic Review. *Clin Infect Dis* (2019) 69(10):1703–11.
- 535 21. Chuang H, Sakaguchi M, Lucky AB, Yamagishi J, Katakai Y, Kawai S, *et al.* SICA-mediated
536 cytoadhesion of *Plasmodium knowlesi*-infected red blood cells to human umbilical vein endothelial
537 cells. *Sci Rep* (2022) 12(1):1–12.
- 538 22. Mohanty S, Sahu PK, Pattnaik R, Majhi M, Maharana S, Bage J, *et al.* Evidence of Brain Alterations in
539 Noncerebral Falciparum Malaria. *Clin Infect Dis* (2022) 75(1):11–8.

- 540 23. Sahu PK, Hoffmann A, Majhi M, Pattnaik R, Patterson C, Mahanta KC, et al. Brain Magnetic
541 Resonance Imaging Reveals Different Courses of Disease in Pediatric and Adult Cerebral Malaria. *Clin*
542 *Infect Dis* (2021) 73(7):e2387–96.
- 543 24. Wang F, Zou ZR, Yuan D, Gong Y, Zhang L, Chen X, et al. Correlation between serum S100 β protein
544 levels and cognitive dysfunction in patients with cerebral small vessel disease: A case-control study.
545 *Biosci Rep* (2017) 37(2).
- 546 25. Rogan A, Sik A, Dickinson E, Patel V, Peckler B, McQuade D, et al. Diagnostic performance of S100B
547 as a rule-out test for intracranial pathology in head-injured patients presenting to the emergency
548 department who meet NICE Head Injury Guideline criteria for CT-head scan. *Emerg Med J* (2023)
549 40(3):159–66.
- 550 26. Conroy AL, Datta D, Hoffmann A, Wassmer SC. The kidney–brain pathogenic axis in severe falciparum
551 malaria. *Trends Parasitol* (2023) 39(3):191–9.
- 552 27. Grigg MJ, William T, Barber BE, Rajahram GS, Menon J, Schimann E, et al. Age-Related Clinical
553 Spectrum of *Plasmodium knowlesi* Malaria and Predictors of Severity. *Clin Infect Dis* (2018) 67(3):350–
554 9.
- 555 28. Jeslyn WPS, Huat TC, Vernon L, Irene LMZ, Sung LK, Jarrod LP, et al. Molecular epidemiological
556 investigation of *Plasmodium knowlesi* in humans and macaques in Singapore. *Vector Borne Zoonotic*
557 *Dis* (2011) 11(2):131–5.
- 558 29. Noordin NR, Lee PY, Mohd Bukhari FD, Fong MY, Abdul Hamid MH, Jelip J, et al. Prevalence of
559 Asymptomatic and/or Low-Density Malaria Infection among High-Risk Groups in Peninsular Malaysia.
560 *Am J Trop Med Hyg* (2020) 103(3):1107–10.
- 561 30. Westwood S, Baird AL, Anand SN, Nevado-Holgado AJ, Kormilitzin A, Shi L, et al. Validation of
562 Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease
563 Multimodal Biomarker Discovery Cohort. *J of Alzheimers Dis* (2020) 74(1):213–25.
- 564 31. Ripamonti E, Edén A, Nilsson S, Sönerborg A, Zetterberg H, Gisslén M. Longitudinal decline of
565 plasma neurofilament light levels after antiretroviral initiation in people living with HIV. *J Intern Med*
566 (2023) 293(4):445–56.
- 567 32. Herman LS, Fornace K, Phelan J, Grigg MJ, Anstey NM, William T, et al. Identification and validation of
568 a novel panel of *Plasmodium knowlesi* biomarkers of serological exposure. *PLoS Negl Trop Dis* (2018)
569 12(6):e0006457.
- 570 33. Fornace KM, Herman LS, Abidin TR, Chua TH, Daim S, Lorenzo PJ, et al. Exposure and infection to
571 *Plasmodium knowlesi* in case study communities in Northern Sabah, Malaysia and Palawan, The
572 Philippines. *PLoS Negl Trop Dis* (2018) 12(6):e0006432.
- 573 34. Fornace KM, Brock PM, Abidin TR, Grignard L, Herman LS, Chua TH, et al. Environmental risk factors
574 and exposure to the zoonotic malaria parasite *Plasmodium knowlesi* across northern Sabah, Malaysia:
575 a population-based cross-sectional survey. *Lancet Planet Health* (2019) 3(4):e179–86.
- 576 35. Longley RJ, White MT, Takashima E, Brewster J, Morita M, Harbers M, et al. Development and
577 validation of serological markers for detecting recent *Plasmodium vivax* infection. *Nat Med* (2020)
578 26(5):741–9.
- 579 36. Drakeley CJ, Corran PH, Coleman PG, Tongren JE, McDonald SLR, Carneiro I, et al. Estimating
580 medium- and long-term trends in malaria transmission by using serological markers of malaria
581 exposure. *Proc Natl Acad Sci* (2005) 102(14):5108–13.

- 582 37. Rogier E, Nace D, Dimbu PR, Wakeman B, Pohl J, Beeson JG, *et al.* Framework for Characterizing
583 Longitudinal Antibody Response in Children After *Plasmodium falciparum* Infection. *Front Immunol*
584 (2021) 12:617951.
- 585 38. Tetteh KKA, Wu L, Hall T, Ssewanyana I, Oulton T, Patterson C, *et al.* Optimisation and
586 standardisation of a multiplex immunoassay of diverse *Plasmodium falciparum* antigens to assess
587 changes in malaria transmission using sero-epidemiology. *Wellcome Open Res.* (2020) 4:26.
- 588 39. Michetti F, D'Ambrosi N, Toesca A, Puglisi MA, Serrano A, Marchese E, *et al.* The S100B story: from
589 biomarker to active factor in neural injury. *J Neurochem* (2019) 148(2):168–87.
- 590 40. Mohanty S, Sahu PK, Pattnaik R, Majhi M, Maharana S, Bage J, *et al.* Evidence of Brain Alterations in
591 Noncerebral Falciparum Malaria. *Clin Infect Dis* (2022) 75(1):11–8.
- 592 41. Kawata K, Liu CY, Merkel SF, Ramirez SH, Tierney RT, Langford D. Blood biomarkers for brain injury:
593 What are we measuring? *Neurosci Biobehav Rev* (2016) 68:460–73.
- 594 42. Datta D, Bangirana P, Opoka RO, Conroy AL, Co K, Bond C, *et al.* Association of Plasma Tau With
595 Mortality and Long-term Neurocognitive Impairment in Survivors of Pediatric Cerebral Malaria and
596 Severe Malarial Anemia. *JAMA Netw Open* (2021) 4(12):e2138515–e2138515.
- 597 43. Thelin EP, Zeiler FA, Ercole A, Mondello S, Büki A, Bellander BM, *et al.* Serial sampling of serum
598 protein biomarkers for monitoring human traumatic brain injury dynamics: A systematic review. *Front*
599 *Neurol* (2017) 8:277421.
- 600 44. Datta D, Gopinadhan A, Soto A, Bangirana P, Opoka RO, Conroy AL, *et al.* Blood biomarkers of
601 neuronal injury in paediatric cerebral malaria and severe malarial anaemia. *Brain Commun* (2023)
602 5(6):fcad323.
- 603 45. Zubelzu M, Morera-Herreras T, Irastorza G, Gómez-Esteban JC, Murueta-Goyena A. Plasma and
604 serum alpha-synuclein as a biomarker in Parkinson's disease: A meta-analysis. *Parkinsonism Relat*
605 *Disord* (2022) 99:107–15.
- 606 46. Çevik S, Özgenç MM, Güneyk A, Evran Ş, Akkaya E, Çalış F, *et al.* NRG1, S100B and GFAP levels
607 are significantly increased in patients with structural lesions resulting from mild traumatic brain injuries.
608 *Clin Neurol Neurosurg* (2019) 183:105380.
- 609 47. Yang J, Korley FK, Dai M, Everett AD. Serum neurogranin measurement as a biomarker of acute
610 traumatic brain injury. *Clin Biochem* (2015) 48(13–14):843–8.
- 611 48. Dietrick B, Molloy E, Massaro AN, Strickland T, Zhu J, Slevin M, *et al.* Plasma and Cerebrospinal Fluid
612 Candidate Biomarkers of Neonatal Encephalopathy Severity and Neurodevelopmental Outcomes. *J*
613 *Pediatr* (2020) 226:71-79.e5.
- 614 49. Bazarian JJ, Biberthaler P, Welch RD, Lewis LM, Barzo P, Bogner-Flatz V, *et al.* Serum GFAP and
615 UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre
616 observational study. *Lancet Neurol* (2018) 17(9):782–9.
- 617 50. Eide PK, Lashkarivand A, Pripp A, Valnes LM, Hovd MH, Ringstad G, *et al.* Plasma neurodegeneration
618 biomarker concentrations associate with glymphatic and meningeal lymphatic measures in neurological
619 disorders. *Nat Commun* (2023) 14(1):1–14.
- 620 51. Shen XN, Huang SY, Cui M, Zhao QH, Guo Y, Huang YY, *et al.* Plasma Glial Fibrillary Acidic Protein in
621 the Alzheimer Disease Continuum: Relationship to Other Biomarkers, Differential Diagnosis, and
622 Prediction of Clinical Progression. *Clin Chem* (2023) 69(4):411–21.

- 623 52. Chouliaras L, Thomas A, Malpetti M, Donaghy P, Kane J, Mak E, et al. Differential levels of plasma
624 biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal
625 dementia and progressive supranuclear palsy. *J Neurol Neurosurg Psychiatry* (2022) 93(6):651–8.
- 626 53. Kim BY, Lee SH, Graham PL, Angelucci F, Lucia A, Pareja-Galeano H, et al. Peripheral Brain-Derived
627 Neurotrophic Factor Levels in Alzheimer's Disease and Mild Cognitive Impairment: a Comprehensive
628 Systematic Review and Meta-analysis. *Mol Neurobiol* (2017) 54(9):7297–311.
- 629 54. Karimi N, Ashourizadeh H, Akbarzadeh Pasha B, Haghshomar M, Jouzdani T, Shobeiri P, et al. Blood
630 levels of brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis (MS): A systematic
631 review and meta-analysis. *Mult Scler Relat Disord* (2022) 65:103984.
- 632 55. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, et al. Multiplexed Immunoassay
633 Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis. *PLoS One*
634 (2011) 6(4):e18850.
- 635 56. Abdi IY, Bartl M, Dakna M, Abdesselem H, Majbour N, Trenkwalder C, et al. Cross-sectional proteomic
636 expression in Parkinson's disease-related proteins in drug-naïve patients vs healthy controls with
637 longitudinal clinical follow-up. *Neurobiol Dis* (2023) 177:105997.
- 638 57. Yang X, Zou M, Pang X, Liang S, Sun C, Wang J, et al. The association between NCAM1 levels and
639 behavioral phenotypes in children with autism spectrum disorder. *Behav Brain Res* (2019) 359:234–8.
- 640 58. Zhao J, Lu W, Li J, Liu L, Zhao X. Decreased Serum NCAM Levels Associated with Cognitive
641 Impairment in Vascular Dementia. *Dis Markers* (2021) 2021:2792884.
- 642 59. Patra K, Soosaipillai A, Sando SB, Lauridsen C, Berge G, Møller I, et al. Assessment of kallikrein 6 as
643 a cross-sectional and longitudinal biomarker for Alzheimer's disease. *Alzheimers Res Ther* (2018)
644 10(1):1–11.
- 645 60. Jha MK, Lee S, Park DH, Kook H, Park KG, Lee IK, et al. Diverse functional roles of lipocalin-2 in the
646 central nervous system. *Neurosci Biobehav Rev* (2015) 49:135–56.
- 647 61. Sahu PK, Hoffmann A, Majhi M, Pattnaik R, Patterson C, Mahanta KC, et al. Brain Magnetic
648 Resonance Imaging Reveals Different Courses of Disease in Pediatric and Adult Cerebral Malaria. *Clin*
649 *Infect Dis* (2021) 73(7):e2387–96.
- 650 62. Balanza N, Francis CK, Crowley VM, Weckman AM, Zhong K, Baro B, et al. Neurofilament Light Chain
651 as a Biomarker of Neuronal Damage in Children With Malaria. *J Infect Dis* (2024) 229(1):183–8.
- 652 63. Chen Y, Chan CK, Kerishnan JP, Lau YL, Wong YL, Gopinath SCB. Identification of circulating
653 biomarkers in sera of *Plasmodium knowlesi*-infected malaria patients - comparison against
654 *Plasmodium vivax* infection. *BMC Infect Dis* (2015) 15(1):1–10.
- 655 64. Wenisch C, Linnau KF, Looaresuwan S, Rumpold H. Plasma Levels of the Interleukin-6 Cytokine
656 Family in Persons with Severe *Plasmodium falciparum* Malaria. *J Infect Dis* [Internet]. 1999 Mar 1 [cited
657 2023 Nov 8];179(3):747–50. Available from: <https://dx.doi.org/10.1086/314630>
- 658 65. De Jong GM, Slager JJ, Verbon A, Van Hellemond JJ, Van Genderen PJJ. Systematic review of the
659 role of angiotensin-1 and angiotensin-2 in *Plasmodium* species infections: biomarkers or therapeutic
660 targets? *Malar J* (2016) 15(1):1–12.
- 661 66. Jain V, Lucchi NW, Wilson NO, Blackstock AJ, Nagpal AC, Joel PK, et al. Plasma levels of
662 angiotensin-1 and -2 predict cerebral malaria outcome in Central India. *Malar J* (2011) 10(1):1–7.
- 663 67. Gomes LT, Alves ER, Rodrigues-Jesus C, Nery AF, Gasquez-Martin TO, Fontes CJ. Angiotensin-2
664 and Angiotensin-2/Angiotensin-1 Ratio as Indicators of Potential Severity of *Plasmodium vivax*
665 Malaria in Patients with Thrombocytopenia. *PLoS One* (2014) 9(10):e109246.

- 666 68. Jain V, Thomas T, Basak S, Sharma RK, Singh N. Sequential dysregulated plasma levels of
667 angiopoietins (ANG-2 and ratios of ANG-2/ANG-1) are associated with malaria severity and mortality
668 among hospital admitted cases in South Bastar Region of Chhattisgarh, Central India. *Pathog Glob*
669 *Health* (2022) 116(1):47–58.
- 670 69. Oluboyo AO, Chukwu SI, Oluboyo BO, Odewusi OO. Evaluation of Angiopoietins 1 and 2 in Malaria-
671 Infested Children. *J Environ Public Health* (2020) 2020:2169763.
- 672 70. Conroy AL, Lafferty EI, Lovegrove FE, Krudsood S, Tangpukdee N, Liles WC, *et al.* Whole blood
673 angiopoietin-1 and-2 levels discriminate cerebral and severe (non-cerebral) malaria from
674 uncomplicated malaria. *Malar J* (2009) 8(1):1–7.
- 675 71. Ouma BJ, Ssenkusu JM, Shabani E, Datta D, Opoka RO, Idro R, *et al.* Endothelial Activation, Acute
676 Kidney Injury, and Cognitive Impairment in Pediatric Severe Malaria. *Crit Care Med* (2020)
677 48(9):E734–43.
- 678 72. Raza A, Ghanchi NK, Zubairi ABS, Raheem A, Nizami S, Beg MA. Tumor Necrosis Factor - α ,
679 Interleukin-10, Intercellular and Vascular Adhesion Molecules Are Possible Biomarkers of Disease
680 Severity in Complicated *Plasmodium vivax* Isolates from Pakistan. *PLoS One* (2013) 8(12):e81363.
- 681 73. Fernandez-Camacho B, Peña-Calero B, Guillermo-Roman M, Ruiz-Cabrejos J, Barboza JL, Bartolini-
682 Arana L, *et al.* Malaria seroepidemiology in very low transmission settings in the Peruvian Amazon. *Sci*
683 *Rep* (2024) 14(1):1–14.
- 684 74. Pinkevych M, Petravic J, Chelimo K, Kazura JW, Moormann AM, Davenport MP. The Dynamics of
685 Naturally Acquired Immunity to *Plasmodium falciparum* Infection. *PLoS Comput Biol* (2012)
686 8(10):e1002729.
- 687 75. Chiu PY, Yang FC, Chiu MJ, Lin WC, Lu CH, Yang SY. Relevance of plasma biomarkers to
688 pathologies in Alzheimer's disease, Parkinson's disease and frontotemporal dementia. *Sci Rep* (2022)
689 12(1):1–9.
- 690 76. Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, *et al.* High performance plasma
691 amyloid- β biomarkers for Alzheimer's disease. *Nature* (2018) 554(7691):249–54.
- 692 77. Cheng L, Li W, Chen Y, Lin Y, Wang B, Guo Q, *et al.* Plasma A β as a biomarker for predicting A β -PET
693 status in Alzheimer's disease : a systematic review with meta-analysis. *J Neurol Neurosurg Psychiatry*
694 (2022) 93(5):513–20.
- 695 78. Rodríguez-Rodríguez A, Egea-Guerrero JJ, Gordillo-Escobar E, Enamorado-Enamorado J,
696 Hernández-García C, Ruiz de Azúa-López Z, *et al.* S100B and Neuron-Specific Enolase as mortality
697 predictors in patients with severe traumatic brain injury. *Neurol Res* (2016) 38(2):130–7.
- 698 79. Böhmer AE, Oses JP, Schmidt AP, Perón CS, Krebs CL, Oppitz PP, *et al.* Neuron-specific enolase,
699 S100B, and glial fibrillary acidic protein levels as outcome predictors in patients with severe traumatic
700 brain injury. *Neurosurgery* (2011) 68(6):1624–30.
- 701 80. Li X, Wang X, Guo L, Wu K, Wang L, Rao L, *et al.* Association between lipocalin-2 and mild cognitive
702 impairment or dementia: A systematic review and meta-analysis of population-based evidence. *Ageing*
703 *Res Rev* (2023) 89:101984.
- 704 81. Shi Y, Luan D, Song R, Zhang Z. Value of peripheral neurotrophin levels for the diagnosis of
705 depression and response to treatment: A systematic review and meta-analysis. *Eur*
706 *Neuropsychopharmacol* (2020) 41:40–51.
- 707 82. Qin XY, Wu HT, Cao C, Loh YP, Cheng Y. A meta-analysis of peripheral blood nerve growth factor
708 levels in patients with schizophrenia. *Mol Psychiatry* (2017) 22(9):1306–12.

- 709 83. Gao W, Zhang Z, Lv X, Wu Q, Yan J, Mao G, *et al.* Neurofilament light chain level in traumatic brain
710 injury: A system review and meta-analysis. *Medicine* (2020) 99(38):e22363.
- 711 84. Zhao Y, Xin Y, Meng S, He Z, Hu W. Neurofilament light chain protein in neurodegenerative dementia:
712 A systematic review and network meta-analysis. *Neurosci Biobehav Rev* (2019) 102:123–38.
- 713 85. Katunina EA, Blokhin V, Nodel MR, Pavlova EN, Kalinkin AL, Kucheryanu VG, *et al.* Searching for
714 Biomarkers in the Blood of Patients at Risk of Developing Parkinson's Disease at the Prodromal Stage.
715 *Int J Mol Sci* (2023) 24(3):1842.
- 716 86. Rogan A, O'Sullivan MB, Holley A, McQuade D, Larsen P. Can serum biomarkers be used to rule out
717 significant intracranial pathology in emergency department patients with mild traumatic brain injury? A
718 Systemic Review & Meta-Analysis. *Injury* (2022) 53(2):259–71.
- 719 87. Wang F, Zou ZR, Yuan D, Gong Y, Zhang L, Chen X, *et al.* Correlation between serum S100 β protein
720 levels and cognitive dysfunction in patients with cerebral small vessel disease: A case-control study.
721 *Biosci Rep* (2017) 37(2):BSR20160446.
- 722 88. Katisko K, Huber N, Kokkola T, Hartikainen P, Krüger J, Heikkinen AL, *et al.* Serum total TDP-43 levels
723 are decreased in frontotemporal dementia patients with C9orf72 repeat expansion or concomitant
724 motoneuron disease phenotype. *Alzheimers Res Ther* (2022) 14(1):1–10.
- 725 89. Ren Y, Li S, Chen S, Sun X, Yang F, Wang H, *et al.* TDP-43 and Phosphorylated TDP-43 Levels in
726 Paired Plasma and CSF Samples in Amyotrophic Lateral Sclerosis. *Front Neurol* (2021) 12:663637.
- 727 90. Villaverde C, Namazzi R, Shabani E, Park GS, Datta D, Hanisch B, *et al.* Retinopathy-Positive
728 Cerebral Malaria Is Associated With Greater Inflammation, Blood-Brain Barrier Breakdown, and
729 Neuronal Damage Than Retinopathy-Negative Cerebral Malaria. *J Pediatric Infect Dis Soc* (2020)
730 9(5):580–6.
- 731 91. Datta D, Conroy AL, Castelluccio PF, Ssenkusu JM, Park GS, Opoka RO, *et al.* Elevated
732 Cerebrospinal Fluid Tau Protein Concentrations on Admission Are Associated With Long-term
733 Neurologic and Cognitive Impairment in Ugandan Children With Cerebral Malaria. *Clin Infect Dis*
734 (2020) 70(6):1161–8.
- 735 92. Erdman LK, Petes C, Lu Z, Dhabangi A, Musoke C, Cserti-Gazdewich CM, *et al.* Chitinase 3-like 1 is
736 induced by *Plasmodium falciparum* malaria and predicts outcome of cerebral malaria and severe
737 malarial anaemia in a case-control study of African children. *Malar J* (2014) 13(1):1–11.
- 738 93. Conroy AL, Hawkes MT, Elphinstone R, Opoka RO, Namasopo S, Miller C, *et al.* Chitinase-3-like 1 is a
739 biomarker of acute kidney injury and mortality in paediatric severe malaria. *Malar J* (2018) 17(1):1–11.

740

741

742 **11 Figure legends**743 **Figure 1. Sample collection sites.**

744 Samples from *Pk*-infected patients were collected from government hospitals and private clinics in Johor,
 745 Selangor, Pahang, Perak, and Trengganu states (red). Samples from community-matched, age-matched
 746 uninfected controls were collected via active sample screening of communities in Johor, Selangor, Negeri
 747 Sembilan, and Kedah (yellow). Map was created in R with RStudio using Leaflet (<https://leafletjs.com/>) and
 748 OpenStreetMap (<https://www.openstreetmap.org>). An interactive version of the map can be found in GitHub
 749 (https://github.com/Cescualito/LSHTM_Wassmer_Pknowlesi_Malaysia).

750 **Figure 2. Group comparisons: Levels of blood circulating biomarkers of brain injury.**

751 **α Syn**: alpha-Synuclein; **APP**: amyloid-beta precursor protein; **A β ₁₋₄₂**: amyloid beta (1-42); **BDNF**: brain-
 752 derived neurotrophic factor; **CaBP**: Calbindin D; **CNS**: central nervous system; **CNTF**: ciliary neurotrophic
 753 factor; **CNTN1**: contactin-1; **CSF**: cerebrospinal fluid; **ENO2 / NSE**: Enolase 2 / Neuron-specific Enolase;
 754 **AHSG**: alpha 2-HS glycoprotein; **FGF-21**: fibroblast growth factor 21; **GDNF**: glial cell line-derived
 755 neurotrophic factor; **GFAP**: glial fibrillary acidic protein; **KLK6**: kallikrein 6 / neurosin; **NCAM-1**: neural cell
 756 adhesion molecule; **NGAL**: neutrophil gelatinase-associated lipocalin (also known as Lipocalin-2); **NGF- β** :
 757 nerve growth factor beta; **NfL**: neurofilament light chain; **NRGN**: neurogranin; **Park7**: Parkinsonism-associated
 758 deglycase; **RNA**: ribonucleic acid; **S100 β** : S100 calcium-binding protein β ; **TDP-43**: TAR DNA-binding protein
 759 43; **Tau**: total Tau protein; **Tau pT181**: phosphorylated Tau protein; **UCH-L1**: ubiquitin carboxy-terminal
 760 hydrolase L1; **YKL40**: Chitinase-3-like protein 1. Wilcoxon test results: * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$;
 761 **** $p < 0.0001$; ns: no significance.

762 **Figure 3. Hierarchical clustering heatmaps: Distinct circulating biomarker profiles between groups.**

763 **Fig 3A. Biomarkers of brain alterations or cerebral injury:** **α Syn**: alpha-Synuclein; **APP**: amyloid-beta
 764 precursor protein; **A β ₁₋₄₂**: amyloid beta (1-42); **BDNF**: brain-derived neurotrophic factor; **CaBP**: Calbindin D;
 765 **CNTN1**: contactin-1; **CSF**: cerebrospinal fluid; **ENO2 / NSE**: Enolase 2 / Neuron-specific Enolase; **GFAP**: glial
 766 fibrillary acidic protein; **KLK6**: kallikrein 6 / neurosin; **NCAM-1**: neural cell adhesion molecule; **Lipocalin-2**:
 767 neutrophil gelatinase-associated lipocalin; **NGF- β** : nerve growth factor beta; **NfL**: neurofilament light chain;
 768 **NRGN**: neurogranin; **Park7**: Parkinsonism-associated deglycase; **S100B**: S100 calcium-binding protein β ;

769 **TDP-43**: TAR DNA-binding protein 43; **Tau**: total Tau protein; **UCH-L1**: ubiquitin carboxy-terminal hydrolase
770 L1; **YKL40**: Chitinase-3-like protein 1.

771 **Fig 3B. Biomarkers of infection and immune activation**: **CCL2**: chemokine (C-C motif) ligand 2; **CCL4**:
772 chemokine (C-C motif) ligands 4; **CCL5**: chemokine (C-C motif) ligand 5; **CCL18**: chemokine (C-C motif)
773 ligand 18; **CRP**: C-reactive protein; **GM-CSF**: granulocyte-macrophage colony-stimulating factor; **IFN- γ** :
774 interferon gamma; **IL-1 α** : interleukin 1 alpha; **IL-1 β** : interleukin 1 beta; **IL-1RA**: interleukin 1RA; **IL-2**:
775 interleukin 2; **IL-4**: interleukin 4; **IL-6**: interleukin 6; **IL-8**: interleukin 8; **IL-10**: interleukin 10; **IL-17A**: interleukin
776 17; **MIF**: migration inhibitory factor; **MPO**: myeloperoxidase; **OPN**: osteopontin; **RAGE**: receptor for advanced
777 glycation end-products; **TNF- α** : tumour Necrosis Factor alpha.




778 **Fig 3C. Vascular biomarkers**: **Ang-1**: angiopoietin-1; **Ang-2**: angiopoietin-2; **Ang-2/Ang-1**: ratio between
779 Ang-2 and Ang-1; **BMP-9**: bone morphogenetic protein 9; **ICAM-1**: intercellular adhesion molecule 1; **PDGF-**
780 **AA**: platelet-derived growth factor AA; **PDGF-BB**: platelet-derived growth factor BB; **Serpin E1**: Serine
781 Proteinase Inhibitor family E1; **VCAM-1**: vascular cell adhesion molecule; **VEGF**: vascular endothelial growth
782 factor; **vWF-A2**: von Willebrand Factor (A2 domain). Data is scaled.

783


784 12 Table legends

785 Table 1. Plasma biomarkers of brain alterations or cerebral injury.

786 **α Syn**: alpha-Synuclein; **APP**: amyloid-beta precursor protein; **A β ₁₋₄₂**: amyloid beta (1-42); **BDNF**: brain-
787 derived neurotrophic factor; **CaBP**: Calbindin D; **CNS**: central nervous system; **CNTF**: ciliary neurotrophic
788 factor; **CNTN1**: contactin-1; **CSF**: cerebrospinal fluid; **ENO2 / NSE**: Enolase 2 / Neuron-specific Enolase;
789 **AHSG**: alpha 2-HS glycoprotein; **FGF-21**: fibroblast growth factor 21; **GDNF**: glial cell line-derived
790 neurotrophic factor; **GFAP**: glial fibrillary acidic protein; **KLK6**: kallikrein 6 / neurosin; **NCAM-1**: neural cell
791 adhesion molecule; **NGAL**: neutrophil gelatinase-associated lipocalin (also known as Lipocalin-2); **NGF- β** :
792 nerve growth factor beta; **NfL**: neurofilament light chain; **NRGN**: neurogranin; **Park7**: Parkinsonism-associated
793 deglycase; **RNA**: ribonucleic acid; **S100 β** : S100 calcium-binding protein β ; **TDP-43**: TAR DNA-binding protein
794 43; **Tau**: total Tau protein; **Tau pT181**: phosphorylated Tau protein; **UCH-L1**: ubiquitin carboxy-terminal
795 hydrolase L1; **YKL40**: Chitinase-3-like protein 1. Biomarker descriptions are extracted from **UniProt**
796 (www.uniprot.org, last accessed January 2024).

797 **Legend:** Clinical findings related to:  *Plasmodium falciparum* malaria infection;  *Plasmodium knowlesi*
798 malaria infection;  Neurological conditions.

799 **Figure 1. Sample collection sites.**



800

801

Figure 2. Group comparisons: Levels of blood circulating biomarkers of brain alterations or cerebral injury.




Figure 3. Hierarchical clustering heatmaps: Distinct circulating biomarker profiles between groups.
























Table 1 Plasma biomarkers of brain alterations or cerebral injury

Marker	Description	Clinical significance
αSyn	Neuronal intracellular protein. Regulates synaptic vesicle trafficking and neurotransmitter release. Its aggregation in the brain is associated with neurodegeneration.	 Plasma α Syn levels were higher in Parkinson's Disease patients than healthy controls and patients with neurodegenerative diseases (45,75).
APP	Neuronal transmembrane protein. Involved in the generation of synapses and axons, neurite growth, and neuronal adhesion. Undergoes proteolytic processes to generate A β .	 In Japanese and Australian cohorts encompassing cognitively normal individuals, subjects with mild cognitive impairment, and Alzheimer's Disease patients, plasma APP/A β ratio predicted individual brain A β levels determined by PET imaging (76).
Aβ₁₋₄₂	APP-derived peptide. The imbalance between A β production and clearance, its misfolding, and accumulation in the extracellular space, are early factors in Alzheimer's disease.	 Lower A β ₁₋₄₂ plasma levels were associated with A β deposition in the brain of patients with varied degrees of cognitive decline, compared with other groups (77).
BDNF	Neurotrophic factor. Major regulator of synaptic transmission and plasticity in adult synapses. Homeostatic regulator of intrinsic neuronal excitability.	 Compared with healthy controls, plasma BDNF levels were increased in patients with certain conditions such as early Alzheimer's Disease— and decreased in patients diagnosed with multiple sclerosis (53,54).
CaBP	Cytosolic protein. Binds calcium with high affinity and regulates its availability in the cytoplasm, playing a role in transepithelial calcium transport.	 Increased CSF levels could predict risk of future dementia in US patients who were cognitively normal at time of recruitment (55).
CNTN1	Membrane protein, participates in nervous system development and neuronal-glia interactions in myelinated nerves.	 Compared to healthy patients, downregulated CNTN1 serum levels predicted cognitive and motor impairment in German patients with Parkinson's Disease (56).
ENO2 / NSE	Dimeric isoform of enolase, an enzyme involved in the metabolic process of glycolysis, relatively specific to neurons.	 Plasma levels are significantly higher in patients with traumatic brain injury, compared with healthy controls (43,78,79).
Fetuin A	Serum glycoprotein, produced by hepatocytes, adipocytes, and choroid plexus cells. Involved in brain development, endocytosis, and bone tissue formation.	 Compared with healthy controls, serum levels were significantly higher in Malaysian patients with malaria, as revealed by two-dimensional electrophoresis and mass spectrometry analysis (63).
GFAP	Intermediate filament protein, specific to astrocytes. Involved in cell-cell communication and blood brain barrier functioning.	 Used in clinical settings to determine injury severity and case management after traumatic brain injury  In Norwegian patients with CSF disorders, higher plasma GFAP concentrations were associated with impaired lymphatic function (50).  In Chinese and UK cohorts, plasma GFAP level ranges distinguished patients with neurodegenerative diseases (51,52).
KLK6	Serine protease, also known as neurosin. Participates in degradation processes against proteins such as APP or α Syn.	 Plasma levels were significantly increased in Swedish patients with advanced Alzheimer's Disease, compared with healthy controls (59).
NCAM-1	Cell surface glycoprotein, expressed in neurons and glia. Involved in cell-cell adhesion, neurite outgrowth, synaptic plasticity, learning, and memory.	 Plasma levels were significantly lower in Chinese children with autistic spectrum disorder. Levels were negatively correlated with a battery of neurocognitive scores (57).

Bertran-Cobo *et al.*

NGAL	Iron-trafficking protein. Participates in innate immunity by binding iron and impeding its uptake by bacteria, which limits their growth. Also plays a role in renal development.	 	Compared with uncomplicated cases, plasma levels were significantly higher in Indian adults with <i>falciparum</i> cerebral malaria and discriminated between fatal and nonfatal outcomes (61).
			Compared with non-dementia controls, plasma levels are significantly higher in patients with Alzheimer's Disease (80).
NGF-β	Neurotrophic factor. Regulates proliferation, differentiation, and survival of sympathetic and sensory neurons.		Compared with healthy controls, plasma levels are lower in patients with major depressive disorder and patients with schizophrenia (81,82).
NfL	Subunit of intermediate filament proteins, exclusive to neurons. Highly expressed in axons, also present in dendrites and neuronal bodies.	 	Plasma levels were significantly higher in Ugandan children with <i>falciparum</i> cerebral malaria and malarial anaemia, compared with asymptomatic community children. Elevated levels associated with cognitive outcomes and mortality in children with cerebral malaria (44).
		 	Longitudinal analysis in Mozambican children with uncomplicated and severe <i>falciparum</i> malaria revealed that while plasma levels were similar upon admission, they increased over time, particularly in severe cases with neurological symptoms (62).
			Increased plasma levels are detected in patients with traumatic or vascular injury, neuroinflammation, and neurodegeneration (43,83,84).
NRGN	Postsynaptic neuronal protein, expressed primarily in dendritic spines. Involved in the protein kinase C signalling pathway, regulates calmodulin availability.		Compared with healthy newborns, plasma levels were significantly higher in Irish babies with neonatal encephalopathy, and they were inversely associated with neurodevelopmental cognitive, motor, and language scores (48).
			Serum concentrations were significantly higher in Turkish and US patients with mild and acute traumatic brain injury, respectively, when compared with healthy controls (46,47).
Park7	Enzyme found in many tissues and organs, including the brain. Has a protective role against oxidative stress and cell death.		Compared to those of healthy controls, lymphocytes from patients at risk of developing prodromal Parkinson's Disease showed a decrease in the expression of Park7 (85).
S100β	Neurotrophic factor. Promotes astrogliosis and axonal proliferation. Highly expressed in astrocytes, it is one of the most abundant soluble proteins in the brain.		Increased plasma levels serve as a blood biomarker of cerebral small vessel disease and intracranial haemorrhage (39,86,87).
			Plasma levels were increased in Indian patients with <i>falciparum</i> severe malaria, compared with uncomplicated cases (40).
TDP-43	RNA-binding protein. Regulates the processing of RNAs involved in neuronal survival, as well as mRNAs that encode proteins relevant for neurodegenerative diseases.		Serum levels are decreased in patients with certain neurodegenerative diseases, such as frontotemporal dementia (88) and increased in other pathologies, such as sporadic amyotrophic lateral sclerosis (89).
Tau	Microtubule-associated protein, used as a biomarker of neuronal injury. Promotes microtubule assembly and stability, involved in neuronal polarity. Forms insoluble aggregates.	 	Plasma levels were increased in Ugandan children with <i>falciparum</i> cerebral malaria or severe malarial anaemia, compared with healthy controls. Plasma levels were associated with mortality and poor cognitive outcomes (44).

Brain injury biomarkers in *P. knowlesi* infection

	filaments that accumulate as neurofibrillary tangles in Alzheimer's Disease.		neurocognitive impairment in young children with cerebral malaria (42).
		 	In Ugandan children with falciparum cerebral malaria, elevated CSF levels were associated with in disease severity, malaria retinopathy, acute kidney injury, prolonged coma duration, and persist neurologic deficits up to 2 years post-discharge (90,91).
UCH-L1	Ubiquitin-protein hydrolase. Processes ubiquitin precursors and ubiquitinated proteins. Associated with neurofibrillary tangles in Alzheimer's Disease.	 	Plasma levels were significantly higher in Ugandan children with falciparum cerebral malaria and malarial anaemia, compared with asymptomatic community children. Elevated levels were linked to brain barrier dysfunction and neurodeficits over follow-up (44).
YKL-40	Glycoprotein secreted by macrophages and other inflammatory cells during differentiation.	 	In Ugandan children with falciparum malaria, plasma levels were significantly increased in severe anaemia and cerebral malaria versus uncomplicated malaria. Among severe cases, admission plasma predicted mortality with high sensitivity and specificity (92).
			In Ugandan children with severe <i>falciparum</i> malaria, admission plasma levels were elevated in cases subsequently died. Levels correlated with markers of inflammation and endothelial activation (93).